TABLE 2.
Combination therapy during the interval between the initial and subsequent carbapenem-resistant K. pneumoniae strains
| Antibiotic therapy | No. (%) of patients receiving therapy in group |
P value | |
|---|---|---|---|
| Case (n = 35) |
Control (n = 18) |
||
| Combination therapy | 21 (60) | 17 (94) | 0.008 |
| Colistin + tigecycline | 13 (37) | 14 (78) | 0.005 |
| Colistin + carbapenema | 11 (31) | 9 (50) | 0.187 |
| Colistin + aminoglycosideb | 2 (6) | 0 (0) | 0.543 |
| Colistin + tigecycline + carbapenema | 4 (11) | 4 (22) | 0.421 |
| Colistin + aminoglycosideb + carbapenema | 1 (3) | 0 (0) | 1.000 |
a
Includes ertapenem, imipenem-cilastatin, meropenem, and doripenem.
b
Includes amikacin and gentamicin.